Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Lobe Sciences Ltd. C.LOBE

Alternate Symbol(s):  LOBEF

Healthcare Drug Manufacturers - Major
Lobe Sciences is a leading “BioPsychedelic” company entering clinical stage development focused on transforming psychedelic medicine to benefit patients of all ages. We are engaged in research and development using psychedelic and non-psychedelic compounds targeting the 5HT2 receptor family. Our team is made up of biotech executives who collectively have managed the development and regulatory... see more

CSE:LOBE - Post Discussion

Lobe Sciences Ltd. > Lobe Sciences Announces Commercial Distribution Agreement
View:
Post by Betteryear2 on May 17, 2023 5:20pm

Lobe Sciences Announces Commercial Distribution Agreement

VANCOUVER, British Columbia--()--Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat orphan diseases today announced it has entered into a commercial distribution agreement for the supply and distribution of Altemia™ with Pentec Health, Inc. (“Pentec Health”), a nationwide provider of clinical nutrition and specialty care services addressing complex needs for patients. Altemia™ is Lobe’s proprietary formulation of emulsified docosahexaenoic acid ethyl ester (“DHA”) concentration designed for patients with sickle cell disease (“SCD”).

Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia™ | Business Wire

Be the first to comment on this post
Lobe Sciences Ltd.